$OCUL
OCULAR THERAPEUTIX, INC

2016 Q1 Form 10-K Financial Statement

#000119312516499184 Filed on March 10, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q4 2015
Revenue $458.0K $436.0K $1.750M
YoY Change 7.51% -13.66% 126.68%
Cost Of Revenue $99.00K $90.00K $319.0K
YoY Change 76.79% 200.0% 250.55%
Gross Profit $359.0K $340.0K $1.431M
YoY Change -2.97% -29.17% 110.13%
Gross Profit Margin 78.38% 77.98% 81.77%
Selling, General & Admin $3.795M $3.730M $13.02M
YoY Change 37.3% 29.97% 46.34%
% of Gross Profit 1057.1% 1097.06% 909.64%
Research & Development $7.073M $6.890M $26.61M
YoY Change 49.88% 33.79% 40.95%
% of Gross Profit 1970.19% 2026.47% 1859.61%
Depreciation & Amortization $205.0K $200.0K $754.0K
YoY Change 18.5% 17.65% 37.84%
% of Gross Profit 57.1% 58.82% 52.69%
Operating Expenses $10.97M $10.62M $39.95M
YoY Change 45.47% 32.42% 43.35%
Operating Profit -$10.51M -$10.28M -$38.20M
YoY Change 47.74% 36.15% 40.98%
Interest Expense $418.0K -$360.0K $1.724M
YoY Change -17.23% -12.2% 54.07%
% of Operating Profit
Other Income/Expense, Net -$331.0K $0.00 -$1.551M
YoY Change -28.82% -0.19%
Pretax Income -$10.84M -$10.64M -$39.75M
YoY Change 43.01% 33.84% 38.74%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$10.84M -$10.64M -$39.75M
YoY Change 43.05% 33.73% 38.75%
Net Earnings / Revenue -2366.81% -2439.68% -2271.31%
Basic Earnings Per Share
Diluted Earnings Per Share -$438.0K -$430.8K -$1.710M
COMMON SHARES
Basic Shares Outstanding 24.75M shares 24.73M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 Q4 2015
SHORT-TERM ASSETS
Cash & Short-Term Investments $95.46M $105.1M $105.1M
YoY Change 41.58% 40.41% 40.51%
Cash & Equivalents $46.21M $30.78M $30.80M
Short-Term Investments $49.24M $74.28M $74.30M
Other Short-Term Assets $1.300M $1.600M $1.600M
YoY Change -13.33% 77.78% 77.78%
Inventory $127.0K $134.0K $100.0K
Prepaid Expenses
Receivables $200.0K $193.0K $200.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $97.10M $107.0M $107.0M
YoY Change 39.77% 40.43% 40.42%
LONG-TERM ASSETS
Property, Plant & Equipment $3.107M $3.095M $3.100M
YoY Change 72.71% 73.68% 72.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K $200.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $3.335M $3.323M $3.300M
YoY Change 64.53% 65.32% 65.0%
TOTAL ASSETS
Total Short-Term Assets $97.10M $107.0M $107.0M
Total Long-Term Assets $3.335M $3.323M $3.300M
Total Assets $100.4M $110.3M $110.3M
YoY Change 40.47% 41.07% 41.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.063M $1.957M $2.000M
YoY Change -6.01% 48.71% 53.85%
Accrued Expenses $2.779M $3.379M $3.400M
YoY Change 44.59% 12.04% 13.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.200M $0.00 $0.00
YoY Change -58.62% -100.0% -100.0%
Total Short-Term Liabilities $6.003M $5.378M $5.400M
YoY Change -16.94% -8.44% -8.47%
LONG-TERM LIABILITIES
Long-Term Debt $14.20M $15.30M $15.30M
YoY Change 17.36% 13.33% 13.33%
Other Long-Term Liabilities $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Liabilities $14.30M $15.40M $15.40M
YoY Change 17.21% 13.24% 13.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.003M $5.378M $5.400M
Total Long-Term Liabilities $14.30M $15.40M $15.40M
Total Liabilities $20.26M $20.72M $20.70M
YoY Change 4.31% 6.26% 6.15%
SHAREHOLDERS EQUITY
Retained Earnings -$140.0M -$129.2M
YoY Change 44.34% 44.45%
Common Stock $220.2M $218.8M
YoY Change 47.7% 47.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $80.17M $89.59M $89.60M
YoY Change
Total Liabilities & Shareholders Equity $100.4M $110.3M $110.3M
YoY Change 40.47% 41.07% 41.05%

Cashflow Statement

Concept 2016 Q1 2015 Q4 2015
OPERATING ACTIVITIES
Net Income -$10.84M -$10.64M -$39.75M
YoY Change 43.05% 33.73% 38.75%
Depreciation, Depletion And Amortization $205.0K $200.0K $754.0K
YoY Change 18.5% 17.65% 37.84%
Cash From Operating Activities -$9.260M -$8.630M -$33.74M
YoY Change 34.59% 53.29% 64.59%
INVESTING ACTIVITIES
Capital Expenditures $127.0K -$470.0K $1.778M
YoY Change -64.12% 6.82% 41.11%
Acquisitions
YoY Change
Other Investing Activities $25.00M -$1.610M -$36.79M
YoY Change -242.86% -95.69% -1.45%
Cash From Investing Activities $24.87M -$2.090M -$38.57M
YoY Change -239.33% -94.47% -0.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -190.0K 300.0K 65.70M
YoY Change 35.71% -372.73% -16.8%
NET CHANGE
Cash From Operating Activities -9.260M -8.630M -33.74M
Cash From Investing Activities 24.87M -2.090M -38.57M
Cash From Financing Activities -190.0K 300.0K 65.70M
Net Change In Cash 15.42M -10.42M -6.610M
YoY Change -162.0% -76.05% -133.25%
FREE CASH FLOW
Cash From Operating Activities -$9.260M -$8.630M -$33.74M
Capital Expenditures $127.0K -$470.0K $1.778M
Free Cash Flow -$9.387M -$8.160M -$35.52M
YoY Change 29.76% 57.23% 63.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24750281 shares
CY2015Q2 dei Entity Public Float
EntityPublicFloat
371000000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-46611000
CY2012Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
268000
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19815000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23854000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-59472000
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
254000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
25776000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17505000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1611991 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.24
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21333507 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21333507 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
148122000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
254000
CY2014Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
13511000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1495000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
58696000
CY2014Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
389000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
338000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
112000
CY2014Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
188000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1316000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3016000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-89428000
CY2014Q4 us-gaap Liabilities
Liabilities
19497000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78193000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2221000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5874000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
36825000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
37435000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37393000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4003000
CY2014Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1354000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1050000
CY2014Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
95000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15243000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
36825000
CY2014Q4 us-gaap Assets
Assets
78193000
CY2014Q4 us-gaap Inventory Net
InventoryNet
133000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
329000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1782000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
228000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Assets Current
AssetsCurrent
76183000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
37435000
CY2014Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
2204000
CY2014Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6000
CY2014Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
37435000
CY2014Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
32000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
893000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
29464000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2582000
CY2014Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
15746000
CY2014Q4 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
540000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2115519 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.78
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24750281 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.57
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1064373 shares
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24750281 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.05
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2078345 shares
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
676000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
820000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
218830000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
507000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2015Q4 us-gaap Liabilities
Liabilities
20718000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
110306000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2939000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1758000
CY2015Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
15272000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1582000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
89588000
CY2015Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
389000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
471000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
68000
CY2015Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
42000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1957000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3379000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-129176000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5378000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51969000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-68000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
262000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2091000
CY2015Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
75000
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4984000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
22554000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
51969000
CY2015Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
68000
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
11325000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
5872000
CY2015Q4 us-gaap Assets
Assets
110306000
CY2015Q4 us-gaap Inventory Net
InventoryNet
134000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
193000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3095000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
228000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2015Q4 us-gaap Assets Current
AssetsCurrent
106983000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
74280000
CY2015Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
1915000
CY2015Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
18000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
74280000
CY2015Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
74348000
CY2015Q4 ocul Net Operating Loss Carryforwards Related To Exercise Of Stock Options
NetOperatingLossCarryforwardsRelatedToExerciseOfStockOptions
1876000
CY2015Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
41000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1592000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30784000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6034000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5897000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
4052000
CY2015Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
21357000
CY2015Q4 ocul Share Based Compensation Arrangement By Share Based Payment Award Nonvested Stock Options Outstanding Held By Nonemployees
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonvestedStockOptionsOutstandingHeldByNonemployees
6195 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.066 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.048 pure
CY2015Q4 ocul Income Tax Examination Likelihood Of Favorable Settlement
IncomeTaxExaminationLikelihoodOfFavorableSettlement
0.50 pure
CY2015Q4 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
430000
CY2014Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.378 pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12645000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M17D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0123 pure
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.11
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13416167 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.340 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.013 pure
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-14000
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.441 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.51
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.746 pure
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2609020 shares
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2013 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1818000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
387000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-13317000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13344000
CY2013 us-gaap Interest Paid
InterestPaid
289000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
476000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-118000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-12903000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14000
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-414000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
250000
CY2013 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
-27000
CY2013 us-gaap Investment Income Net
InvestmentIncomeNet
13000
CY2013 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-26000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13317000
CY2013 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
136000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
476000
CY2013 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
27000
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-14000
CY2013 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
250000
CY2013 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
625000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
448000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6349000
CY2013 us-gaap Operating Expenses
OperatingExpenses
12903000
CY2013 us-gaap Interest Expense
InterestExpense
441000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-387000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
6683000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10517000
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-210000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
CY2013 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
8494000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1761000
CY2013 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
46000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
38000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-174000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
404000
CY2013 ocul Increase In Deferred Tax Assets Valuation Allowance
IncreaseInDeferredTaxAssetsValuationAllowance
5961000
CY2013 ocul Inventory Costs
InventoryCosts
51000
CY2013 ocul Transfers Between Fair Value Measurement Levels
TransfersBetweenFairValueMeasurementLevels
0
CY2013 ocul Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
0
CY2013 ocul Decrease In Deferred Tax Asset Valuation Allowance
DecreaseInDeferredTaxAssetValuationAllowance
0
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.008 pure
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-20496000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M16D
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0224 pure
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.69
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1730136 shares
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.340 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.016 pure
CY2014 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
380000
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.387 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.025 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.046 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.55
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.765 pure
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10652865 shares
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2014 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2273000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1260000
CY2014 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
37326000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-28648000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
35000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28659000
CY2014 us-gaap Sales Revenue Net
SalesRevenueNet
772000
CY2014 us-gaap Interest Paid
InterestPaid
844000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2644000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
69518000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
36000
CY2014 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
64000
CY2014 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3018000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-27094000
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
133000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-442000
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1554000
CY2014 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
74355000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
79000
CY2014 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
-11000
CY2014 us-gaap Investment Income Net
InvestmentIncomeNet
7000
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-4000
CY2014 us-gaap Contracts Revenue
ContractsRevenue
312000
CY2014 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-19000
CY2014 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-57000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28648000
CY2014 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
460000
CY2014 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
169000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
2644000
CY2014 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
11000
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
380000
CY2014 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
64000
CY2014 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3113000
CY2014 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
24000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-62000
CY2014 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1982000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
649000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
19888000
CY2014 us-gaap Operating Expenses
OperatingExpenses
27866000
CY2014 us-gaap Interest Expense
InterestExpense
1119000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-38586000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
78970000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18880000
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1946000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
35000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6913000
CY2014 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
103000
CY2014 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
74354000
CY2014 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
2364000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
323000
CY2014 us-gaap Cost Of Goods Sold
CostOfGoodsSold
91000
CY2014 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
69518000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
507000
CY2014 ocul Insurance Premium Financed By Third Party
InsurancePremiumFinancedByThirdParty
623000
CY2014 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
14877000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
547000
CY2014 ocul Conversion Of Preferred Stock Warrants To Common Stock Warrants
ConversionOfPreferredStockWarrantsToCommonStockWarrants
960000
CY2014 ocul Increase In Deferred Tax Assets Valuation Allowance
IncreaseInDeferredTaxAssetsValuationAllowance
11049000
CY2014 ocul Transfers Between Fair Value Measurement Levels
TransfersBetweenFairValueMeasurementLevels
0
CY2014 ocul Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
0
CY2014 ocul Decrease In Deferred Tax Asset Valuation Allowance
DecreaseInDeferredTaxAssetValuationAllowance
0
CY2014 ocul Stock Issued During Period Value Common Stock And Restricted Stock
StockIssuedDuringPeriodValueCommonStockAndRestrictedStock
0
CY2014 ocul Adjustment To Paid In Capital Conversion Of Preferred Stock Warrants To Common Stock Warrants
AdjustmentToPaidInCapitalConversionOfPreferredStockWarrantsToCommonStockWarrants
960000
CY2014 ocul Premium On Marketable Securities
PremiumOnMarketableSecurities
133000
CY2014 ocul Initial Public Offering Cost Incurred During Noncash Or Partial Noncash Transaction
InitialPublicOfferingCostIncurredDuringNoncashOrPartialNoncashTransaction
95000
CY2014 ocul Repayments Of Insurance Costs Financed By Third Party
RepaymentsOfInsuranceCostsFinancedByThirdParty
233000
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.002 pure
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-33743000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0167 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
34855 shares
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.71
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2134458 shares
CY2015 dei Document Type
DocumentType
10-K
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0001393434
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M12D
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.61
CY2015 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.340 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.012 pure
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 50px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Concentration of Credit Risk and of Significant Suppliers</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company has all cash and cash equivalents and marketable securities balances at one accredited financial institution, in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company is dependent on a small number of third-party manufacturers to supply products for research and development activities in its preclinical and clinical programs and for sales of its ReSure Sealant product. The Company&#x2019;s development programs as well as revenue from future sales of ReSure Sealant could be adversely affected by a significant interruption in the supply of any of the components of these products.</p> </div>
CY2015 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders.
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.381 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.031 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.020 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
28.47
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Entity Registrant Name
EntityRegistrantName
Ocular Therapeutix, Inc.
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
680231 shares
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.46
CY2015 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.12
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, including clinical trials, and the valuation of common stock and stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#x2019;s estimates.</p> </div>
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
141848 shares
CY2015 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.711 pure
CY2015 dei Trading Symbol
TradingSymbol
OCUL
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23244162 shares
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000 pure
CY2015 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y10M2D
CY2015 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1500000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1778000
CY2015 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
91684000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-39748000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
207000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-39748000
CY2015 us-gaap Sales Revenue Net
SalesRevenueNet
1750000
CY2015 us-gaap Interest Paid
InterestPaid
1251000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4640000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
66176000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
53000
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
249000
CY2015 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
564000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-38197000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1551000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-136000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-68000
CY2015 us-gaap Investment Income Net
InvestmentIncomeNet
166000
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
3000
CY2015 us-gaap Contracts Revenue
ContractsRevenue
396000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
60000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39816000
CY2015 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-68000
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1354000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
293000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
4640000
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2015 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
249000
CY2015 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
564000
CY2015 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
283000
CY2015 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3852000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
778000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6609000
CY2015 us-gaap Operating Expenses
OperatingExpenses
39947000
CY2015 us-gaap Interest Expense
InterestExpense
1724000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-38569000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
65703000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-146000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
207000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9165000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26611000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
7000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
219000
CY2015 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
66176000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
348000
CY2015 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
54826000
CY2015 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1897000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
754000
CY2015 ocul Increase In Deferred Tax Assets Valuation Allowance
IncreaseInDeferredTaxAssetsValuationAllowance
15144000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.45
CY2015Q3 us-gaap Sales Revenue Net
SalesRevenueNet
429000
CY2015 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
166000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3192000
CY2015 us-gaap Cost Of Goods Sold
CostOfGoodsSold
319000
CY2015 ocul Transfers Between Fair Value Measurement Levels
TransfersBetweenFairValueMeasurementLevels
0
CY2015 ocul Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
0
CY2015 ocul Maturity Period For Marketable Securities Classified As Available For Sale
MaturityPeriodForMarketableSecuritiesClassifiedAsAvailableForSale
P1Y
CY2015 ocul Decrease In Deferred Tax Asset Valuation Allowance
DecreaseInDeferredTaxAssetValuationAllowance
0
CY2015 ocul Insurance Premium Financed By Third Party
InsurancePremiumFinancedByThirdParty
706000
CY2015 ocul Non Cancelable Operating Leases Expiration Dates
NonCancelableOperatingLeasesExpirationDates
June 2017 and June 2018
CY2015 ocul Minimum Percentage Of Change In Ownership For Limitation On Utilization Of Operating Loss Carryforwards
MinimumPercentageOfChangeInOwnershipForLimitationOnUtilizationOfOperatingLossCarryforwards
0.50 pure
CY2015 ocul Premium On Marketable Securities
PremiumOnMarketableSecurities
338000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-7008000
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7014000
CY2015 ocul Repayments Of Insurance Costs Financed By Third Party
RepaymentsOfInsuranceCostsFinancedByThirdParty
762000
CY2015 ocul Stock Issued During Period Value Common Stock Warrants Cashless Exercise Provision
StockIssuedDuringPeriodValueCommonStockWarrantsCashlessExerciseProvision
0
CY2014Q1 us-gaap Sales Revenue Net
SalesRevenueNet
27000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6825000
CY2014Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
27000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-7578000
CY2015Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7578000
CY2015Q1 us-gaap Sales Revenue Net
SalesRevenueNet
426000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7113000
CY2015Q1 us-gaap Contracts Revenue
ContractsRevenue
188000
CY2015Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
238000
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.10
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-6392000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6397000
CY2014Q2 us-gaap Sales Revenue Net
SalesRevenueNet
97000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5946000
CY2014Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
97000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-10009000
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10009000
CY2015Q2 us-gaap Sales Revenue Net
SalesRevenueNet
459000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9635000
CY2015Q2 us-gaap Contracts Revenue
ContractsRevenue
125000
CY2015Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
334000
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-7294000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7294000
CY2014Q3 us-gaap Sales Revenue Net
SalesRevenueNet
143000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6776000
CY2014Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
143000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-11524000
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11524000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11174000
CY2015Q3 us-gaap Contracts Revenue
ContractsRevenue
41000
CY2015Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
388000
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-7954000
CY2014Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7954000
CY2014Q4 us-gaap Sales Revenue Net
SalesRevenueNet
505000
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-7547000
CY2014Q4 us-gaap Contracts Revenue
ContractsRevenue
312000
CY2014Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
193000
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-10637000
CY2015Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10637000
CY2015Q4 us-gaap Sales Revenue Net
SalesRevenueNet
436000
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-10275000
CY2015Q4 us-gaap Contracts Revenue
ContractsRevenue
42000
CY2015Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
394000

Files In Submission

Name View Source Status
0001193125-16-499184-index-headers.html Edgar Link pending
0001193125-16-499184-index.html Edgar Link pending
0001193125-16-499184.txt Edgar Link pending
0001193125-16-499184-xbrl.zip Edgar Link pending
d46606d10k.htm Edgar Link pending
d46606dex231.htm Edgar Link pending
d46606dex311.htm Edgar Link pending
d46606dex312.htm Edgar Link pending
d46606dex321.htm Edgar Link pending
d46606dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g46606g02x12.jpg Edgar Link pending
g46606g22o78.jpg Edgar Link pending
g46606g22r35.jpg Edgar Link pending
g46606g24x40.jpg Edgar Link pending
g46606g29j33.jpg Edgar Link pending
g46606g36u49.jpg Edgar Link pending
g46606g38i82.jpg Edgar Link pending
g46606g38t81.jpg Edgar Link pending
g46606g40g56.jpg Edgar Link pending
g46606g52d51.jpg Edgar Link pending
g46606g53e92.jpg Edgar Link pending
g46606g56g76.jpg Edgar Link pending
g46606g57k73.jpg Edgar Link pending
g46606g59i26.jpg Edgar Link pending
g46606g62l18.jpg Edgar Link pending
g46606g76i88.jpg Edgar Link pending
g46606g77v62.jpg Edgar Link pending
g46606g92s93.jpg Edgar Link pending
g46606g96k42.jpg Edgar Link pending
ocul-20151231.xml Edgar Link completed
ocul-20151231.xsd Edgar Link pending
ocul-20151231_cal.xml Edgar Link unprocessable
ocul-20151231_def.xml Edgar Link unprocessable
ocul-20151231_lab.xml Edgar Link unprocessable
ocul-20151231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending